Immunobiology of chronic lung allograft dysfunction: New insights from the bench and beyond

R. A. Shilling, D. S. Wilkes

Research output: Contribution to journalShort survey

45 Scopus citations


The first successful human lung transplants were performed in the 1980s. Since that time lung transplantation has been a therapeutic modality for end-stage pulmonary diseases. However, chronic rejection, known as obliterative bronchiolitis (OB)/bronchiolitis obliterans syndrome (BOS), is the key reason why the 5-year survival is only 50%, which is significantly worse than most other solid organ transplants. Recent studies have provided exciting advances that are beginning to be translated into findings in humans. This review will highlight the current advances in understanding the mechanisms of OB/BOS in lung transplant recipients.

Original languageEnglish (US)
Pages (from-to)1714-1718
Number of pages5
JournalAmerican Journal of Transplantation
Issue number8
StatePublished - Aug 1 2009



  • Alloimmunity
  • Autoimmunity
  • Bronchiolitis obliterans syndrome
  • IL-17
  • Lung transplantation
  • Obliterative bronchiolitis

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this